Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells

19 Jul 2018

Abstract excerpt

Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to patients with sickle cell disease and some forms of β-thalassemia. To identify potentially druggable HbF regulators in adult human erythroid cells, we employed a protein kinase domain-focused CRISPR-Cas9-based genetic screen with a newly optimized single-guide RNA scaffold. The screen uncovered the heme-regulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythrocyte Function and Pathophysiology
Share to Hemoglobinopathies and Related Disorders
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30026227
DOI: 10.1126/science.aao0932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cellsPMID 30026227Read ↗

The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expressionSemantic proximity Read ↗

Identification of novel γ-globin inducers among all potential erythroid druggable targetsSemantic proximity Read ↗

Engineering of the Endogenous <i>HBD</i> promoter increases HbA2Semantic proximity Read ↗

Identification and characterization of RBM12 as a novel regulator of fetal hemoglobin expressionSemantic proximity Read ↗

Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell diseaseSemantic proximity Read ↗

Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 <sup>+</sup> cell therapy to induce fetal hemoglobin for sickle cell diseaseSemantic proximity Read ↗

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell diseaseSemantic proximity Read ↗

Elevating fetal hemoglobin: recently discovered regulators and mechanismsSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

Identification of novel HPFH-like mutations by CRISPR base editing that elevates the expression of fetal hemoglobinSemantic proximity Read ↗

Clinically Relevant Gene Editing in Hematopoietic Stem Cells for the Treatment of Pyruvate Kinase Deficiency Hemolytic AnemiaSemantic proximity Read ↗

Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.